V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
Nontyphoidal Salmonella infection among recipients of hematopoietic SCT.
Sanjeet Dadwal,Bernard Tegtmeier,Ryotaro Nakamura,Jane Kriengkauykiat,James I. Ito,S.J. Forman,Vinod Pullarkat +6 more
TL;DR: Food safety practices to prevent NTS infection are important in HSCT recipients, particularly for those who have chronic GVHD after allogeneic HSCT.
Journal ArticleDOI
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia
Ibrahim Aldoss,Salman Otoukesh,Jianying Zhang,Sally Mokhtari,Dat Ngo,Mona Mojtahedzadeh,Monzr M. Al Malki,Amandeep Salhotra,Haris Ali,Ahmed Aribi,Karamjeet S. Sandhu,Shukaib Arslan,Paul Koller,Brian Ball,Forrest Stewart,Peter T. Curtin,Andrew S. Artz,Ryotaro Nakamura,Guido Marcucci,Stephen J. Forman,Anthony S. Stein,Vinod Pullarkat +21 more
TL;DR: In this paper, the authors retrospectively reviewed the outcomes of adult patients with B-cell ALL treated with blinatumomab (n = 132) for either relapsed/refractory (r/r) or minimal residual disease-positive (MRD+) acute lymphoblastic leukemia (ALL).
Journal ArticleDOI
Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.
TL;DR: This review focuses on current efforts to target CD123 in acute leukemia through various therapeutic constructs, and concludes that targeting CD123 represents a promising universal therapeutic target in advanced acute leukemias irrespective of the individual leukemia phenotype.
Journal ArticleDOI
Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.
Ibrahim Aldoss,Tracey Stiller,Joo Y. Song,Monzr M. Al Malki,Haris Ali,Amandeep Salhotra,Ahmed Aribi,Samer K. Khaled,Popsie Gaytan,Joyce Murata-Collins,Joycelynne Palmer,David S. Snyder,Margaret R. O'Donnell,Ryotaro Nakamura,Anthony S. Stein,Stephen J. Forman,Guido Marcucci,Vinod Pullarkat +17 more
TL;DR: In conclusion, the single-institution experience supports the reported superior shortterm prognosis for patients with NPM1 mutated AML, but challenges the accepted notion of favorable long-term outcome in this population.
Journal ArticleDOI
Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT.
Sepideh Shayani,Joycelynne Palmer,Tracy Stiller,H Chan,S Keuylian,Pablo M. Parker,Sandra H. Thomas,Vinod Pullarkat,A P Nademanee,Stephen J. Forman,Ryotaro Nakamura +10 more
TL;DR: Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT and this data supports the use of this drug in patients with SCT-related central giant cell granuloma.